THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or as to what action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are a resident of the United Kingdom or, if not, another appropriately authorised independent professional adviser. This document does not contain nor should its contents be construed as legal, business or tax advice and you should consult your own solicitor, independent financial adviser or tax adviser (as appropriate) for such advice. No person has been authorised to give any information or make any representations other than those contained in this document and, if given or made, such information or representations must not be relied on as having been authorised by CRISM Therapeutics Corporation (the "Company").

If you have sold or otherwise transferred all of your Ordinary Shares, please send this document and the accompanying proxy form as soon as possible to the purchaser or transferee, or to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some (but not all) of your Ordinary Shares, please retain these documents and consult the stockbroker or other agent through whom the sale or transfer was effected.

This document should be read in its entirety. Your attention is drawn to the letter from the Chair in this document, recommending you vote in favour of the resolution to be proposed at the General Meeting.

CRISM Therapeutics Corporation

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

NOTICE OF

ANNUAL GENERAL MEETING

Notice convening a General Meeting of Shareholders to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT, UK on 27 October 2026 at 11.00 a.m. is set out at the end of this document. A Form of Proxy for holders of Ordinary Shares for use at the General Meeting accompanies this document and, to be valid, must be completed and returned to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL.

As an alternative to completing the hard copy Form of Proxy, you can appoint a proxy electronically online via the Investor Centre app or by accessing the web browser at https://uk.investorcentre.mpms.mufg.com/ (refer to the notes to the Notice of Meeting). For an electronic proxy appointment to be valid, your appointment must be received by the Company's registrars, MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event no later than 11.00 a.m. on 23 October 2026.

A Form of Direction for holders of Depository Interests for use at the General Meeting of Shareholders accompanies this document and, to be valid, must be completed and returned to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event to be received not later than 11.00 a.m. on 22 October 2026. The return of one or more completed Forms of Proxy or Forms of Direction will not prevent you from attending the General Meeting and voting in person if you wish to do so (and are so entitled).

Depository Interest holders who are also CREST members may transmit voting instructions by utilising the CREST voting service in accordance with the procedures described in the CREST Manual (refer to the notes to the Notice of Meeting).

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io and refer to the notes to the Notice of Meeting.

A summary of the action to be taken by Shareholders of the Company is set out in the Notice of Meeting at the end of this document. Copies of this document will be available free of charge from the Company's registered office during

normal business hours on each day (excluding Saturday, Sunday and public holidays) from the date hereof until the date of the General Meeting. Copies will also be available from the Company's website at www.crismtherapeutics.com.

DEFINITIONS

The following definitions apply throughout this document, unless the context otherwise requires:

"Annual General Meeting" or "AGM"	the Annual General Meeting of the Company convened for 27 October 2026 to approve the Resolutions, or any adjournment of that meeting;
"Articles"	the memorandum and articles of association of the Company as the same are in force at any applicable time
"Board" or "Directors"	the directors of the Company whose names are set out on page 5 of this document
"**Company"**	CRISM Therapeutics Corporation, a company registered in the British Virgin Islands with registered number 1010359 and having its registered office at Kingston Chambers, P.O. Box 173, Road Town, Tortola, British Virgin Islands
"**CREST**"	the computerised settlement system operated by Euroclear which facilitates the transfer of title to shares in uncertificated form
"**CREST Manual**"	the document of that name issued by Euroclear
"**CREST Voting Instruction**"	a message by or on behalf of Depository Interest holders in connection with the General Meeting transmitted through CREST properly authenticated in accordance with Euroclear's specifications and containing the information required for such instructions in the CREST Manual
"**Depository Interests**"	the Depository interests representing Ordinary Shares
"Euroclear"	Euroclear UK & International Limited, the operator of CREST
"Form of Direction"	the form of direction for use by Depository Interest holders in connection with the General Meeting
"Form of Proxy"	the Form of Proxy for use by Shareholders at the AGM
"Group"	the Company and its subsidiaries
"Notice"	the notice of General Meeting found at the end of this document
"**Ordinary Shares**"	the ordinary shares of no par value in the capital of the Company

"Shareholders"	holders of Ordinary Shares and, where the context requires, Depository Interests

CRISM Therapeutics Corporation

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

Directors:
Dr Charles Spicer (*Non-Executive Chair*)
Andrew Webb (*Chief Executive Officer*)
Professor Chris McConville (*Chief Scientific Officer*)
Gerald Beaney (*Non-Executive Director*)

Registered Office:
Kingston Chambers
P.O. Box 173
Road Town
Tortola
British Virgin Islands

2 October 2026

Notice of Annual General Meeting

Dear Shareholder,

The Company's 2026 AGM will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT on 27 October 2026 at 11.00 am.

The formal Notice convening the General Meeting is included in this Document. A Form of Proxy or a Form of Direction for use in connection with the General Meeting are enclosed with this document.

Business at the AGM

Resolution 1 - Annual Report and Accounts

This is an ordinary resolution to receive, consider and adopt the Directors' Report, the Financial Statements and the Report of the Independent Auditors thereon for the year ended 31 December 2025 (the "**Annual Report and Accounts**").

Resolution 2 – Directors' remuneration report

Shareholders are asked to approve the Directors' remuneration report for the financial year ended 31 December 2025 in the Company's Annual Report and Accounts. This resolution is advisory and the Directors' entitlement to receive remuneration is not conditional on it. If the advisory vote is not carried the Remuneration Committee will consult with shareholders before implementing any changes to Directors' remuneration.

Resolutions 3-6 – Re-election of Directors

In line with the Quoted Company Alliance's Corporate Governance Code (the "**Code**") all Directors retire annually and they offer themselves for re-election at the AGM (to take effect at the conclusion of the AGM).

Biographical details of the Directors seeking re-election can be found on the Company's website at https://www.crismtherapeutics.com/board-and-leadership.

The Board has concluded that each Director standing for re-election continues to make an effective and valuable contribution and demonstrates commitment to the role, making the necessary time available for Board and Committee meetings and other duties as required. Further details can be found in the Governance Report in the Annual Report and Accounts.

Resolution 7 – Appointment of Auditors and remuneration

This is an ordinary resolution to grant the Directors the authority to appoint HaysMac LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting at which the accounts are laid before the Company and to authorise the Directors to determine the auditors' remuneration.

Resolution 8 – Authority to allot Ordinary Shares

Resolution 8 is an ordinary resolution to authorise the Directors to issue and allot Ordinary Shares. The Articles require that the authority of Directors to allot Ordinary Shares and to make offers or agreements to allot Ordinary Shares in the Company or grant rights to subscribe for or convert any security into Ordinary Shares should be subject to the approval of Shareholders in a general meeting except in connection with an employees' share scheme.

Accordingly, Resolution 8 will be proposed to authorise the Directors to allot up to 20,000,000 Ordinary Shares (being approximately 25 per cent. of the Company's issued share capital as at the date of this document). Such authority, if granted, will expire at the conclusion of the next annual general meeting of the Company to be held in 2027.

Resolution 9 – Dis-application of pre-emption rights

Resolution 9 is a special resolution to disapply pre-emption rights in respect of Ordinary Shares. The Articles require that any equity shares issued wholly for cash must be offered to existing Shareholders in proportion to their existing shareholdings unless otherwise approved by Shareholders in a general meeting except in the case of an employees' share scheme. A special resolution will be proposed at the AGM to give the Directors authority to allot equity securities for cash other than on a pro rata basis in respect of the issue of up to 20,000,000 Ordinary Shares (being approximately 25 per cent. of the Company's issued share capital). Such authority will expire at the conclusion of the annual general meeting of the Company to be held in 2027. The special resolution will require votes in favour of not less than 75 per cent. of the votes cast by Shareholders voting in person or by proxy at the AGM in order to be passed.

Action to be taken in respect of the AGM

Whether or not you intend to be present at the Annual General Meeting, shareholders are requested to complete, sign and return your Form of Proxy to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible and in any event not later than 11.00 a.m. on 23 October 2026, being 48 hours (not taking into account any part of a day which is not a working day in England & Wales) before the time appointed for holding the Annual General Meeting.

Completion of a Form of Proxy will not preclude Shareholders from attending the Annual General Meeting and voting in person if they so choose.

Proxies may be appointed by either:

- completing and returning the enclosed proxy form;
- appointing a proxy electronically online at https://uk.investorcentre.mpms.mufg.com/; or
- voting via the Investor Centre app.

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io and refer to the notes to the Notice of Meeting.

As an alternative to completing the hard copy Form of Proxy, you can appoint a proxy electronically online via the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/ (refer to the notes accompanying the Notice of AGM at the end of this document).

In either case, the notice of appointment of a proxy should reach the Company's registrars, MUFG Corporate Markets of PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 11.00 a.m. on 23 October 2026. Please refer to the Notes to the Notice of Annual General Meeting on page 10 and any enclosed proxy form for detailed instructions.

Holders of Depository Interests are requested to complete, sign and return a Form of Direction appointing MUFG Corporate Markets Trustees (Nominees) Limited (the "**Custodian**") to vote the underlying Ordinary Shares on their behalf at the Annual General Meeting to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL, as soon as possible but in any event no later than 11.00 a.m. on 22 October 2026. A holder of Depository Interests has no right to attend and vote in relation to the underlying Ordinary Shares at the Annual General Meeting and should therefore complete and return the Form of Direction so that the Custodian may vote on their behalf. However, if either a holder of Depository Interests or their representative does wish to attend and/or vote at the Annual General Meeting they should request a Letter of Representation from the Custodian in accordance with the instructions on the Form of Direction.

Holders of Depository Interests in CREST may transmit voting instructions by utilising the CREST voting service in accordance with the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider, should refer to their CREST sponsor or voting service provider, who will be able to take appropriate action on their behalf.

In order for instructions made using the CREST voting service to be valid, the appropriate CREST message (a "**CREST Voting Instruction**") must be properly authenticated in accordance with Euroclear's specifications and must contain the information required for such instructions, as described in the CREST Manual (available via www.euroclear.com).

To be effective, the CREST Voting Instruction must be transmitted so as to be received by the Company's agent (ID RA10) no later than 11.00 a.m. on 22 October 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the CREST Voting Instruction by the CREST applications host) from which the Company's agent is able to retrieve the CREST Voting Instruction by enquiry to CREST in the manner prescribed by CREST. Holders of Depository Interests in CREST and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the transmission of CREST Voting Instructions. It is the responsibility of the Depository Interest holder concerned to take (or, if the Depository Interest holder is a CREST personal member or sponsored member or has appointed a voting service provider, to procure that the CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a CREST Voting Instruction is transmitted by means of the CREST voting service by any particular time. In this connection, Depository Interest holders and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your instruction must be lodged by 11.00 a.m. on 22 October 2026 in order to be considered valid or, if the meeting is adjourned, by the time which is 72 hours before the time of the adjourned meeting. Before you can submit an instruction via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic submission of your instruction. An electronic submission via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your submission.

Recommendation

The Board believes that the Resolutions being put to the Shareholders as described in this letter are in the best interests of the Company and its members as a whole and are likely to promote the success of the Company for the benefit of its members as a whole.

Accordingly, the Directors unanimously recommend that you vote in favour of the Resolutions to be proposed at the AGM as they intend to do in respect of their own beneficial holdings.

Yours sincerely

Dr Charles Spicer
Non-Executive Chair

CRISM THERAPEUTICS CORPORATION

(Incorporated and registered in the British Virgin Islands with registered number 1010359)

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting ("**AGM**") of CRISM Therapeutics Corporation (the "**Company**") will be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT, UK at 11.00 a.m. on 27 October 2026 to consider and, if thought fit, pass the following resolutions of which resolutions 1 to 8 will be proposed as ordinary resolutions and resolution 9 will be proposed as a special resolution.

ORDINARY RESOLUTIONS

1. THAT the Directors' Report, the Financial Statements and the Report of the Independent Auditors thereon for the year ended 31 December 2025 (the "**Annual Report and Accounts**") be received and adopted.

2. THAT the Directors' remuneration report set out on pages 22 to 24 of the Company's Annual Report and Accounts be received and approved.

3. THAT Andrew Webb, who retires and offers himself for reappointment as a director of the Company, be re-elected as a Director of the Company.

4. THAT Professor Chris McConville, who retires and offers himself for reappointment as a director of the Company, be re-elected as a Director of the Company.

5. THAT Gerald Beaney, who retires and offers himself for reappointment as a director of the Company, be re-elected as a Director of the Company.

6. THAT Dr Charles Spicer, who retires and offers himself for reappointment as a director of the Company, be re-elected as a Director of the Company.

7. THAT HaysMac LLP be appointed as auditors of the Company to hold office until the conclusion of the next annual general meeting at which accounts are laid before the Company and that the Directors be authorised to agree the remuneration of the auditors of the Company.

8. THAT the Directors be and are hereby generally and unconditionally authorised to exercise all or any of the powers of the Company to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company ("**Relevant Securities**") up to an amount of 20,000,000 Ordinary Shares provided that this authority shall expire (unless previously renewed, varied or revoked by the Company in a meeting of Shareholders) at the conclusion of the Annual General Meeting of the Company to be held in 2027 save that the Company may before such expiry make an offer or agreement which would or might require Relevant Securities to be allotted after such expiry and the Directors may allot Relevant Securities pursuant to any such offer or agreement not withstanding such expiry.

SPECIAL RESOLUTION

9. That the Directors be and they are pursuant to Article 5.4 (a) of the Company's articles of association hereby empowered to allot up to 20,000,000 Ordinary Shares for cash pursuant to the authority conferred by Resolution 8 as if the pre-emption rights in Article 5.3 (a) of the Company's articles of association did not apply to any such allotment provided that the power hereby granted shall expire at the conclusion of the AGM of the Company to be held in 2027, save that the Company may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry, but otherwise in accordance with the foregoing provisions of this power in which case the Directors may allot equity securities in pursuance of such offer or agreement as if the power conferred hereby had not expired.

BY ORDER OF THE BOARD
Dr Charles Spicer
Non-Executive Chair
Dated: 2 October 2026

Registered Office:
Kingston Chambers
P.O. Box 173
Road Town
Tortola
British Virgin Islands

Notes

1. To be valid, the enclosed Form of Proxy for the meeting convened by the above notice and any authority under which it is executed (or a notarially certified copy of such authority) must be deposited at the Company's registrars' office at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL to be received not less than 48 hours before the time for holding the meeting.

Alternatively, shareholders can vote electronically via the Investor Centre, a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below. Alternatively, you may access the Investor Centre via a web browser at: https://uk.investorcentre.mpms.mufg.com/.

Download on the App Store

GET IT ON Google Play

Unless otherwise indicated on the Form of Proxy or any other electronic voting instruction, the proxy will vote as they think fit or, at their discretion, withhold from voting.

2. Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, the time by which a person must be entered on the register of members in order to have the right to vote is close of business on 23 October 2026 (being not more than 48 hours prior to the time fixed for the meeting) or, if the meeting is adjourned, such time being not more than 48 hours prior to the time fixed for the adjourned meeting. Changes to entries on the register of members after that time will be disregarded in determining the right of any person to vote.

3. In the case of joint holders, the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the relevant joint holding.

4. In the case of a corporation, the enclosed Form of Proxy must be executed under its common seal or be signed on its behalf by an attorney or officer duly authorised.

5. Depository Interest Holders wishing to vote in respect of the resolutions to be considered at the Shareholders' Meeting can do so by instructing the Depository. This may be done in the following ways:

(i) Depository Interest Holders who are CREST members may give such an instruction through the CREST electronic voting service in accordance with the procedures described in the CREST Manual. CREST personal Depository Holders or other CREST sponsored members, and those CREST members who have appointed a voting service provider, should refer to their CREST sponsor or voting service provider, who will be able to take the appropriate action on their behalf.

In order for an instruction made by CREST to be valid, the appropriate CREST message ("a CREST proxy instruction") must be properly authenticated in accordance with Euroclear's requirements and must contain information required for such instructions, as described in the CREST Manual. The message, in order to be valid, must be transmitted so as to be received by the Depository's agent, ID RA10 by 11.00 a.m. on 22 October 2026. The time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST applications host) from which the Depository's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. The Depository may treat as invalid a CREST voting instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST proxy instructions. It is the responsibility of the CREST member concerned to take (or to procure that his CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. Please refer to the CREST Manual for further guidance.

(ii) Depository Interest Holders who cannot give voting instructions via CREST should complete the enclosed Form of Direction and submit to the Depository. If the Depository Interest Holder is a corporation then the Form of Direction must be executed by a duly authorised person or under its common seal or in a manner authorised by its constitution. To be valid, Forms of Direction must be received by the Depository no later than 11.00 a.m. on 22 October 2026.

(iii) If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your instruction must be lodged by 22 October 2026 on 11.00 a.m. in order to be considered valid or, if the meeting is adjourned, by the time which is 72 hours before the time of the adjourned meeting. Before you can submit an instruction via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic submission of your instruction. An electronic submission via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your submission.

(iv) To be effective, a valid form of direction (and any power of attorney or other authority under which it is signed) must be received electronically or delivered to MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL, by no later than 11.00 a.m. on 22 October 2026 or 72 hours before any adjourned meeting. You must be registered as holder of the Depository Interests as at close of business on 22 October 2026 (or 72 hours before any adjourned meeting) for your form of direction to be valid.

(v) The Depository will appoint the Chair of the meeting as its proxy to cast its votes. The Chair of the meeting may also vote or abstain from voting as they think fit on any other business (including amendments to resolutions) which may properly come before the meeting. The 'Vote Withheld' option is provided to enable you to abstain from voting on the resolutions. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

(vi) Depository interest holders wishing to attend the meeting should contact the Depository at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds, LS1 4DL or by emailing Nominee.Enquiries@cm.mpms.mufg.com by no later than 11.00 a.m. on 22 October 2026 or 72 hours before any adjourned meeting.